Befotertinib for patients with pretreated EGFR T790M mutated locally advanced or metastatic NSCLC: Final overall survival results from a phase 2 trial.
Shun LuYiping ZhangGuojun ZhangJianying ZhouShundong CangYing ChengGang WuPeiguo CaoDongqing LvHong JianXiangming JinChengshui ChenPanwen TianKai WangGuanming JiangGongyan ChenQun ChenHui ZhaoCuimin DingRenhua GuoGuoping SunBin WangLiyan JiangZhe LiuJian FangJunquan YangWu ZhuangYunpeng LiuJian ZhangYueyin PanJun ChenQitao YuMin ZhaoJiuwei CuiDianming LiTienan YiZhuang YuYan YangYan ZhangXiuyi ZhiYunchao HuangRong WuLiangan ChenAimin ZangLejie CaoQingshan LiXiaoling LiYong SongDonglin WangShucai ZhangLieming DingLing ZhangDong JiZhilin ShenPublished in: Lung cancer (Amsterdam, Netherlands) (2024)
Befotertinib demonstrated a more profound OS benefit compared to other 3rd-generation EGFR TKI, despite that cross trial data comparison should be interpreted with caution. The safety profile was manageable and consistent with previously report data in pretreated patients with confirmed T790M mutation-positive NSCLC.
Keyphrases
- small cell lung cancer
- advanced non small cell lung cancer
- epidermal growth factor receptor
- tyrosine kinase
- locally advanced
- electronic health record
- squamous cell carcinoma
- brain metastases
- big data
- clinical trial
- rectal cancer
- neoadjuvant chemotherapy
- phase iii
- intellectual disability
- phase ii
- radiation therapy
- free survival
- data analysis
- randomized controlled trial
- machine learning
- lymph node
- double blind
- placebo controlled